Oligodeoxynucleotides antisense to c-abl specifically inhibit entry into S-phase of CD34+ hematopoietic cells and their differentiation to granulocyte-macrophage progenitors.
Rosti V
Blood. 86(9):3387-93.
Arachidonic acid induces c-jun gene expression in stromal cells stimulated by interleukin-1 and tumor necrosis factor-alpha: evidence for a tyrosine-kinase-dependent process.
Rizzo MT
Blood. 86(8):2967-75.
Density separation of umbilical cord blood and recovery of hemopoietic progenitor cells: implications for cord blood banking.
Almici C
Stem Cells. 13(5):533-40.
Natural killer cell regeneration after transplantation with mafosfamide purged autologous bone marrow.
Almici C
Bone Marrow Transplant. 16(1):95-101.
Granulocyte colony-stimulating factor (G-CSF) prevents dose-limiting neutropenia in lymphoma patients receiving standard dose chemotherapy.
Dotti G
Haematologica. 80(2):142-5.
Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide.
Carlo-Stella C
Bone Marrow Transplant. 14(3):425-32.
Identification of Philadelphia-negative granulocyte-macrophage colony-forming units generated by stroma-adherent cells from chronic myelogenous leukemia patients.
Carlo-Stella C
Blood. 83(5):1373-80.
Acquired cyclic thrombocytopenia-thrombocytosis with periodic defect of platelet function.
Balduini CL
Br J Haematol. 85(4):718-22.
Use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with lymphoid malignancies transplanted with unpurged or adjusted-dose mafosfamide-purged autologous marrow.
Carlo-Stella C
Blood. 80(9):2412-8.
Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
Carlo-Stella C
Exp Hematol. 20(3):328-33.